Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells
Source abstract
Abstract
Thymoquinone (TQ) is a promising anticancer molecule but its development is hindered by its limited bioavailability. Drug encapsulation is commonly used to overcome low drug solubility, limited bioavailability, and nonspecific targeting. In this project, TQ nanoparticles (TQ-NP) were synthesized and characterized. The cytotoxicity of the NP was investigated in nontumorigenic MCF-10-A breast cells, while the uptake, distribution, as well as the anticancer potential were investigated in MCF-7 and MDA-MB-231 breast cancer cells. Flash Nanoprecipitation and dynamic light scattering coupled with scanning electron microscopy were used to prepare and characterize TQ-NP prior to measuring their anticancer potential by MTT assay. The uptake and subcellular intake of TQ-NP were evaluated by fluorometry and confocal microscopy. TQ-NP were stable with a hydrodynamic average diameter size around 100 nm. Entrapment efficiency and loading content of TQ-NP were high (around 80 and 50 %, respectively). In vitro, TQ-NP had equal or enhanced anticancer activity effects compared to TQ in MCF-7 and aggressive MDA-MB-231 breast cancer cells, respectively, with no significant cytotoxicity of the blank NP. In addition, TQ and TQ-NP were relatively nontoxic to MCF-10-A normal breast cells. TQ-NP uptake mechanism was both time and concentration dependent. Treatment with inhibitors of endocytosis suggested the involvement of caveolin in TQ-NP uptake. This was further confirmed by subcellular localization findings showing the colocalization of TQ-NP with caveolin and transferrin as well as with the early and late markers of endocytosis. Altogether, the results describe an approach for the enhancement of TQ anticancer activity and uncover the mechanisms behind cell-TQ-NP interaction.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nigella sativa pharmacological applications · Nanoparticle-Based Drug Delivery · Drug Transport and Resistance Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Abu-Dahab R, Odeh F, Ismail SI, Azzam H, Al Bawab A (2013) Preparation, characterization and antiproliferative activity of thymoquinone-beta-cyclodextrin self assembling nanoparticles. Pharmazie 68:939–944
2. Ahmad F, Baloch MK, Jamil M, Jeon YJ (2010) Characterization of polystyrene-b-poly(ethylene oxide) diblock copolymer and investigation of its micellization behavior in water. J Appl Polymer Sci. doi: 10.1002/app.3216510.1002/app.32165 ↗
3. Akbulut M, Ginart P, Gindy ME, Theriault C, Chin KH, Soboyejo W, Prud’homme RK (2009) Generic method of preparing multifunctional fluorescent nanoparticles using flash nanoprecipitation. Adv Funct Mater 19:718–725. doi: 10.1002/adfm.20080158310.1002/adfm.200801583 ↗
4. Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, Ahmad FJ (2012) Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomed 7:5705–5718. doi: 10.2147/ijn.s3532910.2147/ijn.s35329 ↗
5. Bhattacharya S et al (2015) PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials 51:91–107 doi: 10.1016/j.biomaterials.2015.01.00710.1016/j.biomaterials.2015.01.007 ↗
6. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659. doi: 10.1016/j.addr.2004.02.01410.1016/j.addr.2004.02.014 ↗
7. Cambon A et al (2013) Poly(styrene oxide)-poly(ethylene oxide) block copolymers: from “classical” chemotherapeutic nanocarriers to active cell-response inducers. J Controll Release 167:68–75. doi: 10.1016/j.jconrel.2013.01.01010.1016/j.jconrel.2013.01.010 ↗
8. Chung YC, Kuo JF, Wei WC, Chang KJ, Chao WT (2015) Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to Trastuzumab Emtansine (T-DM1). PloS one 10:e0133072. doi: 10.1371/journal.pone.013307210.1371/journal.pone.0133072 ↗
9. D’Addio SM et al (2012) Effects of block copolymer properties on nanocarrier protection from in vivo clearance. J Controll Release 162:208–217. doi: 10.1016/j.jconrel.2012.06.02010.1016/j.jconrel.2012.06.020 ↗
10. Dehghani H, Hashemi M, Entezari M, Mohsenifar A (2015) The comparison of anticancer activity of thymoquinone and nanothymoquinone on human breast adenocarcinoma Iranian. J Pharm Res 14:539–546
11. Elsabahy M, Wooley KL (2012) Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41:2545–2561. doi: 10.1039/c2cs15327k10.1039/c2cs15327k ↗
12. Ganea GM, Fakayode SO, Losso JN, van Nostrum CF, Sabliov CM, Warner IM (2010) Delivery of phytochemical thymoquinone using molecular micelle modified poly(D, L lactide-co-glycolide) (PLGA) nanoparticles. Nanotechnology 21:285104. doi: 10.1088/0957-4484/21/28/28510410.1088/0957-4484/21/28/285104 ↗
13. Guler E et al (2014) Bio-active nanoemulsions enriched with gold nanoparticle, marigold extracts and lipoic acid: in vitro investigations Colloids and surfaces B. Biointerfaces 121:299–306. doi: 10.1016/j.colsurfb.2014.05.02610.1016/j.colsurfb.2014.05.026 ↗
14. Gupta VK, Karar PK, Ramesh S, Misra SP, Gupta A (2010) Nanoparticle formulation for hydrophilic & hydrophobic drugs. Int J Res Pharm 1:163–169
15. Han K, Miah MA, Shanmugam S, Yong CS, Choi HG, Kim JA, Yoo BK (2007) Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity. Arch Pharm Res 30:1344–134910.1007/BF02980276 ↗
16. Iversen T-G, Skotland T, Sandvig K (2011) Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6:176–185. doi: 10.1016/j.nantod.2011.02.00310.1016/j.nantod.2011.02.003 ↗
17. Kievit FM, Zhang M (2011) Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (Deerfield Beach, Fla) 23:H217–247 doi: 10.1002/adma.20110231310.1002/adma.201102313 ↗
18. Kim TH, Lee S, Chen X (2013) Nanotheranostics for personalized medicine. Expert Rev Mol Diagn 13:257–269. doi: 10.1586/erm.13.1510.1586/erm.13.15 ↗
19. Kou L, Sun J, Zhai Y, He Z (2013) The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian J Pharm Sci 8:1–10. doi: 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
20. Lai SK, Hida K, Man ST, Chen C, Machamer C, Schroer TA, Hanes J (2007) Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 28:2876–2884. doi: 10.1016/j.biomaterials.2007.02.02110.1016/j.biomaterials.2007.02.021 ↗
21. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controll Release 161:175–187 doi: 10.1016/j.jconrel.2011.09.06310.1016/j.jconrel.2011.09.063 ↗
22. Liu P, Sun Y, Wang Q, Sun Y, Li H, Duan Y (2014) Intracellular trafficking and cellular uptake mechanism of mPEG-PLGA-PLL and mPEG-PLGA-PLL-Gal nanoparticles for targeted delivery to hepatomas. Biomaterials 35:760–770. doi: 10.1016/j.biomaterials.2013.10.02010.1016/j.biomaterials.2013.10.020 ↗
23. Lopez-Davila V, Seifalian AM, Loizidou M (2012) Organic nanocarriers for cancer drug delivery. Curr Opin Pharmacol 12:414–419. doi: 10.1016/j.coph.2012.02.01110.1016/j.coph.2012.02.011 ↗
24. Mohanraj VJ, Chen Y (2006) Nanoparticles—a review. Trop J Pharm Res 5:561–573. doi: 10.4314/tjpr.v5i1.1463410.4314/tjpr.v5i1.14634 ↗
25. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB (2010) Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 80:1833–1843. doi: 10.1016/j.bcp.2010.07.02110.1016/j.bcp.2010.07.021 ↗
26. Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A (2012) Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Delivery 19:371–377. doi: 10.3109/10717544.2012.72750010.3109/10717544.2012.727500 ↗
27. Oh N, Park JH (2014) Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomed 9(Suppl 1):51–63. doi: 10.2147/IJN.S2659210.2147/IJN.S26592 ↗
28. Rajput S et al (2015) Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm 12:4214–4225. doi: 10.1021/acs.molpharmaceut.5b0069210.1021/acs.molpharmaceut.5b00692 ↗
29. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB (2010) Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol 79:1640–1647. doi: 10.1016/j.bcp.2010.01.02310.1016/j.bcp.2010.01.023 ↗
30. Ryan SM, Brayden DJ (2014) Progress in the delivery of nanoparticle constructs: towards clinical translation. Curr Opin Pharmacol 18:120–128. doi: 10.1016/j.coph.2014.09.01910.1016/j.coph.2014.09.019 ↗
31. Saad WS, Prud’homme RK (2016) Principles of nanoparticle formation by flash nanoprecipitation. Nano Today. doi: 10.1016/j.nantod.2016.04.00610.1016/j.nantod.2016.04.006 ↗
32. Schneider-Stock R, Fakhoury IH, Zaki AM, El-Baba CO, Gali-Muhtasib HU (2014) Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today 19:18–30. doi: 10.1016/j.drudis.2013.08.02110.1016/j.drudis.2013.08.021 ↗
33. Shah M, Naseer MI, Choi MH, Kim MO, Yoon SC (2010) Amphiphilic PHA-mPEG copolymeric nanocontainers for drug delivery: preparation, characterization and in vitro evaluation. Int J Pharm 400:165–175. doi: 10.1016/j.ijpharm.2010.08.00810.1016/j.ijpharm.2010.08.008 ↗
34. Shah M, Choi MH, Ullah N, Kim MO, Yoon SC (2011) Synthesis and characterization of PHV-block-mPEG diblock copolymer and its formation of amphiphilic nanoparticles for drug delivery. J Nanosci Nanotechnol 11:5702–571010.1166/jnn.2011.4493 ↗
35. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updates 14:150–163. doi: 10.1016/j.drup.2011.01.00310.1016/j.drup.2011.01.003 ↗
36. Shekunov BY, Chattopadhyay P, Tong HH, Chow AH (2007) Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res 24:203–227. doi: 10.1007/s11095-006-9146-710.1007/s11095-006-9146-7 ↗
37. Sutton KM, Doucette CD, Hoskin DW (2012) NADPH quinone oxidoreductase 1 mediates breast cancer cell resistance to thymoquinone-induced apoptosis. Biochem Biophys Res Commun 426:421–426. doi: 10.1016/j.bbrc.2012.08.11110.1016/j.bbrc.2012.08.111 ↗
38. van Vlerken LE, Amiji MM (2006) Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 3:205–216. doi: 10.1517/17425247.3.2.20510.1517/17425247.3.2.205 ↗
39. Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, Tan KH (2011) Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway. Biochem Pharmacol 82:464–475. doi: 10.1016/j.bcp.2011.05.03010.1016/j.bcp.2011.05.030 ↗
40. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF (2013) Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 65:121–138. doi: 10.1016/j.addr.2012.09.04110.1016/j.addr.2012.09.041 ↗
41. Zamboni WC et al (2012) Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 18:3229–3241. doi: 10.1158/1078-0432.CCR-11-293810.1158/1078-0432.CCR-11-2938 ↗
42. Zeng X, Morgenstern R, Nystrom AM (2014) Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. Biomaterials 35:1227–1239. doi: 10.1016/j.biomaterials.2013.10.04210.1016/j.biomaterials.2013.10.042 ↗